-
Uncategorized5 months ago
Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera option
New China-US biotech gets $54M: Vivatides Therapeutics raised the Series A for its preclinical-stage R&D in siRNA and antisense oligonucleotides aimed at reaching tissues beyond the...
-
Uncategorized5 months agoTrump administration admits a glaring error in its accusations about New York health care fraud
NEW YORK — President Donald Trump’s administration this week acknowledged it made a significant error in figures it used to help justify a fraud probe into New York’s...
-
Uncategorized5 months ago
FDA rejects Replimune’s melanoma prospect for second time
The second time is not the charm for Replimune’s melanoma candidate RP1. After spurning the immunotherapy last July, the FDA has now rejected the biotech’s resubmitted...
-
Uncategorized5 months agoSTAT+: GSK says goodbye to leucovorin (again)
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Buyer beware: If you are an avid consumer...
-
Uncategorized5 months agoThis week in Drug Discovery (6 – 10 April)
News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW. This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition....
-
Uncategorized5 months ago
Novo’s double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim
Novo's double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim
-
Uncategorized5 months agoWomen have awaited a revolution in menopause. It hasn’t arrived.
Persistent barriers are still hindering drug development for a host of menopause symptoms. Read More
-
Uncategorized5 months agoOpinion: What public health can learn from the MAHA movement
I didn’t expect to find myself face to face with leaders and activists from the “Make America Healthy Again” movement in respectful dialogue, or to consider...
-
Uncategorized5 months ago
GSK CEO’s ‘scientific courage’ propels plans for medley of phase 3 trials for Hansoh-partnered ADC
When Fierce last caught up with GSK’s head of oncology R&D back in November, we were told to “stay tuned” for the pharma to publish its...
-
Uncategorized5 months agoCancer Drug Shortfalls Tied to How BET Inhibitors Hit BRD2 and BRD4 Differently
For more than a decade, BET inhibitors have been touted as one of cancer therapy’s most promising drug classes. The logic was straightforward: many tumors rely...
Generic Drugs
China plans to transform $3M biotech sector into $522B powerhouse by 2030
FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
